Research and Markets: The Global Market for Orthobiologics is Projected to More Than Double by 2013 Driven by Technological Advances and Ageing

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/09021c/orthopaedic_market) has
announced the addition of the "Orthopaedic Market Report 2009" report to their
offering.

A thorough assessment of this fast growing industry with 5-year market forecasts
by sector, regional assessment and extensive competitor evaluation.

Key Areas Addressed:

* Market forecasts to 2013 for the major orthopaedic sector markets
* Market share data by company for major product sectors
* Evaluation and market share of orthopaedic markets by geographical region
* Social, market and product growth drivers
* Who's working with whom? Over 70 mergers and alliances reported
* A comprehensive review of 46 leading companies
* A thorough assessment of this fast growing industry with 5-year market
forecasts by sector, regional assessment and extensive competitor evaluation

This report answers key business questions...

* What annual growth is expected for the spinal sector to 2013 and what will the
US$ value be?
* Who are the leading companies in the spinal sector and what % share of the
market do they have?
* Who are the emerging companies that are seeing significant double digit
revenue growth, and what are the products/technologies which are driving that
performance?
* In which geographic region is the orthopaedic market expected to grow with a
CAGR of 13%?
* Since 2006 there have been 36 significant acquisitions - who bought who, for
how much and which sectors were affected?
* Who are German company, co.don's principal competitors?

The recession takes hold but performances are still impressive:

The global orthopaedic market is estimated by Espicom to have been worth
approximately US$37.1 billion in 2008, following growth of 9.7% over the
previous year. Excluding the arthroscopy and 'other' segments (operating theatre
equipment and supplies), the market totalled US$29 billion, having grown by
10.7% over the previous year.

The fastest growing segments are orthobiologics, spinal and trauma, whilst the
established markets for reconstruction implants and arthroscopy equipment are
exhibiting more modest growth rates.

Growth continues to be fuelled by a number of factors, including the ageing
population, the uptake of orthopaedic surgery at an earlier age, physiological
problems due to the increasing incidence of obesity, the development of better
and longer-lasting implants and materials, as well as new procedures, in
particular, minimally-invasive procedures. Long-term social and demographic
trends will underpin the sector's commercial success for many years.

Spinal markets continue rapid growth as innovative companies make their mark The
spinal implant market experienced approximately 15.3% growth, to US$6.8 billion
in 2008. This segment is one of the fastest-growing markets in orthopaedics,
fuelled by the ageing population, treatments for younger patients, the
development of better implants, materials and procedures, higher patient demand
and the move from fusion technologies to motion-preserving devices. In keeping
with the rest of the orthopaedic market, the spine segment will slow in 2009, to
nearer 8.2%.

Medtronic is the clear market leader with over 40% market share, having
bolstered its position with the 2007 acquisition of Kyphon. DePuy held a 16%
share of the market in 2007, followed by Synthes on 13% and Stryker on 9%.
Zimmer signalled its intent in 2008, with the acquisition of Abbott Spine,
giving the company a 6% share of the market. The major spinal manufacturers have
all seen their positions in the market decline in recent years as numerous new
companies enter the spinal market with proprietary technology aimed at improving
current surgical approaches.

Orthobiologics: beginning to deliver the promise:

The global market for orthobiologics was estimated at US$4.8 billion in 2008.
This market is projected to more than double by 2013 driven by technological
advances and an ageing, increasingly active population giving rise to more
people aged over 60 diagnosed with musculoskeletal conditions. Stem-cell
therapies are forecast to be the fastest growing category, boosted by President
Obama's decision to lift the restrictions on US federal funding for research on
new stem cell lines. It is estimated that over 200 companies are developing
orthopaedic biomaterials. While the large multinationals have a significant
presence, the orthobiologics segment is very fragmented and is mainly inhabited
by much smaller companies, many of which are development stage companies with
products that have not yet received regulatory approval. The orthobiologics
market is currently led by Medtronic, with an expanding orthobiologics
portfolio, the lead product of which is the company's InFUSE Bone Graft, which
dominates the bone morphogenic protein market with 90+% market share.

About the Author:

In a career spanning 27 years, Ian Taylor has been involved in the creation,
writing and editing of subscription services, such as Medistat, as well as
contributing to many reports such as Emerging Technologies in Spinal Motion
Preservation and The Global Market for Advanced Woundcare Products.

Some of the Companies mentioned:

* aap Implantate
* Acrobot
* Alphatec Spine
* Artimplant
* Axiom Worldwide
* Biomet
* co.don
* Corin
* Exactech
* Facet Solutions
* Globus Medical
* Integra Life Sciences
* K2M
* KFx Medical
* LDR Holdings
* Life Spine
* Mazor Surgical Technologies
* NuVasive
* Osteotech
* Pioneer Surgical Technology
* RTI Biologics
* Spinal Elements
* Spinal Restoration
* Stryker
* Synthes
* US Spine
* Vertebron
* Wright Medical Technology
* X-spine Systems
* Zimmer

For more information visit
http://www.researchandmarkets.com/research/09021c/orthopaedic_market

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com

Copyright Business Wire 2009